Claire  Poll net worth and biography

Claire Poll Biography and Net Worth

General Counsel of Verona Pharma
From September 2015 to August 2016, Ms Poll served as an advisor to us, where she advised on legal, strategic, corporate, and financing matters. She also served as an Executive Director on our board of directors from September 2006 until September 2016. Ms Poll received a Bachelor of Arts, a Bachelor of Laws and a Bachelor of Jurisprudence from the University of Western Australia and a Diploma in Applied Finance and Investment.

What is Claire Poll's net worth?

The estimated net worth of Claire Poll is at least $27.89 million as of August 7th, 2023. Ms. Poll owns 1,907,367 shares of Verona Pharma stock worth more than $27,885,706 as of December 11th. This net worth estimate does not reflect any other assets that Ms. Poll may own. Additionally, Ms. Poll receives a salary of $356,160.00 as General Counsel at Verona Pharma. Learn More about Claire Poll's net worth.

How old is Claire Poll?

Ms. Poll is currently 56 years old. There are 5 older executives and no younger executives at Verona Pharma. The oldest executive at Verona Pharma is Dr. Kathleen A. Rickard, Chief Medical Officer, who is 65 years old. Learn More on Claire Poll's age.

What is Claire Poll's salary?

As the General Counsel of Verona Pharma plc, Ms. Poll earns $356,160.00 per year. There are 3 executives that earn more than Ms. Poll. The highest earning executive at Verona Pharma is Dr. David S. Zaccardelli, President, CEO & Executive Director, who commands a salary of $1,050,000.00 per year. Learn More on Claire Poll's salary.

How do I contact Claire Poll?

The corporate mailing address for Ms. Poll and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Claire Poll's contact information.

Has Claire Poll been buying or selling shares of Verona Pharma?

Claire Poll has not been actively trading shares of Verona Pharma within the last three months. Most recently, Claire Poll sold 1,512 shares of the business's stock in a transaction on Monday, August 7th. The shares were sold at an average price of $2.47, for a transaction totalling $3,734.64. Following the completion of the sale, the general counsel now directly owns 1,907,367 shares of the company's stock, valued at $4,711,196.49. Learn More on Claire Poll's trading history.

Who are Verona Pharma's active insiders?

Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.

Are insiders buying or selling shares of Verona Pharma?

In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 193,736 shares worth more than $378,874.24. In the last year, insiders at the sold shares 26 times. They sold a total of 8,061,833 shares worth more than $104,534,812.64. The most recent insider tranaction occured on November, 20th when Director Martin Edwards bought 33,736 shares worth more than $62,074.24. Insiders at Verona Pharma own 3.9% of the company. Learn More about insider trades at Verona Pharma.

Information on this page was last updated on 11/20/2023.

Claire Poll Insider Trading History at Verona Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/7/2023Sell1,512$2.47$3,734.641,907,367View SEC Filing Icon  
8/3/2023Sell20,608$2.54$52,344.321,935,231View SEC Filing Icon  
8/1/2023Sell18,608$2.68$49,869.441,968,783View SEC Filing Icon  
5/1/2023Sell80,376$2.58$207,370.081,979,063View SEC Filing Icon  
2/1/2023Sell152,000$2.59$393,680.00774,256View SEC Filing Icon  
12/22/2022Sell240,000$2.69$645,600.00774,256View SEC Filing Icon  
See Full Table

Claire Poll Buying and Selling Activity at Verona Pharma

This chart shows Claire Poll's buying and selling at Verona Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma Company Overview

Verona Pharma logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $14.20
Low: $13.93
High: $14.65

50 Day Range

MA: $14.00
Low: $11.94
High: $15.47

2 Week Range

Now: $14.20
Low: $11.83
High: $26.44


536,315 shs

Average Volume

456,307 shs

Market Capitalization

$9.03 billion

P/E Ratio


Dividend Yield